

Summary

In this domain of the REMAP-CAP trial, participants meeting the platform-entry criteria for REMAP-CAP admitted to participating intensive care units with suspected or microbiological testing-confirmed COVID-19 infection will be randomized to receive one of four interventions:

- No antiviral for COVID-19 (no placebo)
- lopinavir/ritonavir
- hydroxychloroquine
- hydroxychloroquine and lopinavir/ritonavir

This domain will enroll only patients in the pandemic infection is suspected or proven (PISOP) stratum and be analyzed in the Pandemic Statistical Model as outlined from the Pandemic Appendix to Core (PAAtC).

At this participating site the following interventions have been selected within this domain:

- ☐ No antiviral for COVID-19 (no placebo)
- ☐ lopinavir/ritonavir
- ☐ hydroxychloroquine
- ☐ hydroxychloroquine and lopinavir/ritonavir

Is the site participating in this COVID-19 Antiviral Domain? YES/NO

Name Site:

Name PI:

Date:

Signature: